Back to Search
Start Over
Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.
- Source :
-
PloS one [PLoS One] 2019 Sep 18; Vol. 14 (9), pp. e0222178. Date of Electronic Publication: 2019 Sep 18 (Print Publication: 2019). - Publication Year :
- 2019
-
Abstract
- Background: Seasonal influenza results in significant morbidity and mortality worldwide, but the currently licensed inactivated vaccines generally have low vaccine efficacies and could be improved. In this phase 1 clinical trial, we compared seasonal influenza vaccine regimens with different priming strategies, prime-boost intervals, and administration routes to determine the impact of these variables on the resulting antibody response.<br />Methods: Between August 17, 2012 and January 25, 2013, four sites enrolled healthy adults 18-70 years of age. Subjects were randomized to receive one of the following vaccination regimens: trivalent hemagglutinin (HA) DNA prime followed by trivalent inactivated influenza vaccine (IIV3) boost with a 3.5 month interval (DNA-IIV3), IIV3 prime followed by IIV3 boost with a 10 month interval (IIV3-IIV3), or concurrent DNA and IIV3 prime followed by IIV3 boost with a 10 month interval (DNA/IIV3-IIV3). Each regimen was additionally stratified by an IIV3 administration route of either intramuscular (IM) or intradermal (ID). DNA vaccines were administered by a needle-free jet injector (Biojector). Study objectives included evaluating the safety and tolerability of each regimen and measuring the antibody response by hemagglutination inhibition (HAI).<br />Results: Three hundred and sixteen subjects enrolled. Local reactogenicity was mild to moderate in severity, with higher frequencies recorded following DNA vaccine administered by Biojector compared to IIV3 by either route (p <0.02 for pain, swelling, and redness) and following IIV3 by ID route compared to IM route (p <0.001 for swelling and redness). Systemic reactogenicity was similar between regimens. Though no overall differences were observed between regimens, the highest titers post boost were observed in the DNA-IIV3 group by ID route and in the IIV3-IIV3 group by IM route.<br />Conclusions: All vaccination regimens were found to be safe and tolerable. While there were no overall differences between regimens, the DNA-IIV3 group by ID route, and the IIV3-IIV3 group by IM route, showed higher responses compared to the other same-route regimens.<br />Competing Interests: The Emmes Corporation provided support in the form of salaries for authors AB and JM but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section. This support does not alter our adherence to PLOS ONE policies on sharing data and materials.
- Subjects :
- Administration, Intranasal
Adult
Aged
Female
Healthy Volunteers
Hemagglutinins adverse effects
Hemagglutinins immunology
Humans
Immunization, Secondary
Influenza Vaccines adverse effects
Influenza Vaccines immunology
Injections, Intradermal
Male
Middle Aged
Vaccines, DNA adverse effects
Vaccines, DNA immunology
Vaccines, Inactivated administration & dosage
Vaccines, Inactivated adverse effects
Vaccines, Inactivated immunology
Young Adult
Hemagglutinins administration & dosage
Influenza Vaccines administration & dosage
Influenza, Human prevention & control
Vaccines, DNA administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1932-6203
- Volume :
- 14
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- PloS one
- Publication Type :
- Academic Journal
- Accession number :
- 31532789
- Full Text :
- https://doi.org/10.1371/journal.pone.0222178